Alvotech (ALVO)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
$4.09+0.14%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-53.5%
The outlook
Alvotech currently reads as neutral based on buy — 2.2 avg of 4 analysts, mixed vs its moving averages, 18% of the way from its 52-week low to high, avg target +41% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusBuy — 2.2 avg of 4 analysts
Price trendMixed vs its moving averages
52-week range18% of the way from its 52-week low to high
Price targetAvg target +41% vs current price
Analyst price target
~12-month · 4 analysts$5.75average target+40.8% vs now
Now $4.09
Low $4.00High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.38B
52-wk high
$9.25
52-wk low
$2.94
50-day avg
$3.54
200-day avg
$4.49
Trailing P/E
—